Effect of Exercise in children with liver diseases

Not Applicable

• Conditions: Health Condition 1: K740- Hepatic fibrosisHealth Condition 2: K768- Other specified diseases of liver

• Registration Number: CTRI/2023/02/049869
• Lead Sponsor: Institute of Liver and Biliary Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 May 2023

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Children 9 - 18 years age with chronic liver disease & frailty score > 5

Exclusion Criteria

1.Lansky play performance scale <50

2.Unable to do exercise under supervision on at least 2 occasions

3.Children on higher corticosteroid dose ( >0.1mg/kg/day) in last 12 weeks

4.Any degree of musculoskeletal involvement (myopathy/limb deformity/paraplegia)

5.Children with any cardiac disease

6.Children with neurological Wilson

7.Uncontrolled portal hypertension (persistent high-risk varices) Recurrent variceal bleed >= 2

8.Any degree of hemodynamic instability

9.Current hepatic encephalopathy (any grade)

10.Grade 3 ascites

11.Hepatic hydrothorax

12.Any degree of oxygen dependence

13.Severe or Very severe Hepatopulmonary syndrome (room air PaO2 < 60 mm Hg)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of Frailty in children with liver disease and Improvement in Frailty after 12 weeks of exercise therapy in children with CLD and Frailty.Timepoint: 12 weeks

Secondary Outcome Measures

Name	Time	Method
Decrease in myostatin levels after 12 weeks of exercise regimenTimepoint: 12 weeks;Decrease in the occurrence of significant events including HE, UGI bleed, SBP, AKI, new onset or increase in ascites, hospital stay and mortality.Timepoint: 3 months;Increase in skeletal muscle mass in Body composition analysis after 12 weeks of exercise regimenTimepoint: 12 weeks